GlassScriptPhysician profile
Stephanie E Stafford
NPI 1720031321
$3,355.40
in general payments reported to CMS, 2019-2025
43 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $838 · 2021: $387 · 2023: $20.63 · 2024: $378 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.69 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.05 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.87 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $338.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $248.79 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Gilead Sciences, INC. | $187.47 | 2024-2025 | |
| Abbvie INC. | $157.52 | 2020-2025 | |
| Lilly USA, LLC | $157.07 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.39 | 2019-2025 | Xifaxan |
| Collegium Pharmaceutical, INC. | $116.85 | 2020-2021 | |
| Novo Nordisk INC | $110.25 | 2019-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $102.46 | 2024-2025 | |
| Depuy Synthes Sales INC. | $89.06 | 2020-2024 | Monovisc |
| Janssen Pharmaceuticals, INC | $65.52 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $64.53 | 2019-2021 | |
| Allergan, INC. | $63.54 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Stafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.